drugset / Trial / NCT04507165
Opioid-free Anesthesia in VATS Lung Resection
RandomizedParallel-groupDouble-blindTreatment
Summary
A comparison of incidences of postoperative opioid-related adverse effects and recovery parameters in patients undergoing video-assisted thoracoscopic surgery (VATS) lung resection receiving opioid or opioid-free general anesthesia (OFA).
Timeline
- Start
- 2020-08
- Primary completion
- 2021-07
- Completion
- 2022-07
Outcome
Met primary endpoint
paper At 2 h postoperatively, hypotension incidence was lower in the OFA group(8.2%vs 33.3%,P = 0.002),with fewer overall adverse reactions (18.4%vs 39.6%,P = 0.018). PMID 41388253 ↗
Publications
- Background Dinges HC, Otto S, Stay DK, Baumlein S, Waldmann S, Kranke P, Wulf HF, Eberhart LH. Side Effect Rates of Opioids in Equianalgesic Doses via Intravenous Patient-Controlled Analgesia: A Systematic Review and Network Meta-analysis. Anesth Analg. 2019 Oct;129(4):1153-1162. doi: 10.1213/ANE.0000000000003887.
- Background Cozowicz C, Poeran J, Zubizarreta N, Liu J, Weinstein SM, Pichler L, Mazumdar M, Memtsoudis SG. Non-opioid analgesic modes of pain management are associated with reduced postoperative complications and resource utilisation: a retrospective study of obstructive sleep apnoea patients undergoing elective joint arthroplasty. Br J Anaesth. 2019 Jan;122(1):131-140. doi: 10.1016/j.bja.2018.08.027. Epub 2018 Oct 27.
- Background Forget P. Opioid-free anaesthesia. Why and how? A contextual analysis. Anaesth Crit Care Pain Med. 2019 Apr;38(2):169-172. doi: 10.1016/j.accpm.2018.05.002. Epub 2018 Sep 13.
- Zhang R, Wu Y, Wang X, Zhang W, Feng Y. Efficacy of opioid-free anesthesia in reducing postoperative adverse events for thoracoscopic pulmonary surgery: a randomized controlled trial. BMC Anesthesiol. 2025 Dec 12;25(1):607. doi: 10.1186/s12871-025-03497-x.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 0.4 ug/kg | Intravenous |
| Subject | Lidocaine | Other / unclassified | 1.5 mg/kg | Intravenous |
| Subject | Lidocaine | Other / unclassified | 2 mg/kg | Intravenous |
| Comparator | Remifentanil | Small molecule | 0.1 ug/kg | — |
| Comparator | Remifentanil | Small molecule | 0.5 ug/kg | — |
| Comparator | Sufentanil | Other / unclassified | 0.1 ug/kg | Intravenous |
| Subject | tetracaine | Other / unclassified | 5 ml | Other |
| Comparator | Cisatracurium | Small molecule | 0.15 mg/kg | Intravenous |
| Comparator | Cisatracurium | Small molecule | 0.3 mg/kg | Intravenous |
| Comparator | Esmolol | Other / unclassified | 1 mg/kg | Intravenous |
| Comparator | Flurbiprofen | Small molecule | 50 mg | Intravenous |
| Comparator | Methylprednisolone | Other / unclassified | 40 mg | Intravenous |
| Comparator | Propofol | Small molecule | 1.5 mg/kg | Intravenous |
| Comparator | Propofol | Small molecule | 2 mg/kg | Intravenous |
Indications
No indication recorded.